We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$357M
Cap. Flow
+$1.29M
Cap. Flow %
0.04%
Top 10 Hldgs %
74.76%
Holding
30
New
1
Increased
13
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$32.1M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$24.6M
3
RDUS
Radius Health, Inc.
RDUS
+$7.55M
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$6.76M
5
MGNX icon
MacroGenics
MGNX
+$6.56M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$49.7M
2
TSRO
TESARO, Inc.
TSRO
+$24.4M
3
CELG
Celgene Corp
CELG
+$14.4M
4
KITE
Kite Pharma, Inc.
KITE
+$3.71M
5
SAGE
Sage Therapeutics
SAGE
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 90.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$24.4B
$466M 15.26%
3,489,822
-390,000
-10% -$49.7M
CELG
2
DELISTED
Celgene Corp
CELG
$416M 13.59%
3,339,298
-120,000
-3% -$14.4M
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.4B
$300M 9.81%
7,461,295
+548,123
+8% +$24.6M
GILD icon
4
Gilead Sciences
GILD
$165B
$188M 6.16%
2,774,596
– –
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$175M 5.74%
4,540,399
+180,000
+4% +$7.55M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.93B
$166M 5.42%
2,839,528
+30,000
+1% +$1.44M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$126B
$159M 5.21%
1,455,445
+40,000
+3% +$3.52M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$149M 4.88%
1,229,428
– –
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.6B
$139M 4.53%
3,201,552
+50,000
+2% +$2.14M
TSRO
10
DELISTED
TESARO, Inc.
TSRO
$127M 4.15%
824,582
-150,000
-15% -$24.4M
HALO icon
11
Halozyme
HALO
$12.2B
$100M 3.29%
7,749,832
+150,000
+2% +$1.9M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$80.8B
$94.9M 3.11%
245,000
– –
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$69.1M 2.26%
972,439
-50,000
-5% -$2.93M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$29.3B
$63.6M 2.08%
1,241,338
+50,000
+4% +$2.31M
KITE
15
DELISTED
Kite Pharma, Inc.
KITE
$58.1M 1.9%
740,000
-60,000
-8% -$3.71M
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
$49.7M 1.63%
1,408,542
+100,000
+8% +$2.29M
JUNO
17
DELISTED
Juno Therapeutics, Inc.
JUNO
$48.5M 1.59%
2,185,000
+315,000
+17% +$6.76M
MGNX icon
18
MacroGenics
MGNX
$257M
$42M 1.38%
2,260,000
+340,000
+18% +$6.56M
MYOV
19
DELISTED
Myovant Sciences Ltd.
MYOV
$38.8M 1.27%
3,302,835
+110,000
+3% +$1.26M
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
$35.1M 1.15%
1,685,150
– –
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$31.3M 1.02%
1,925,000
+350,000
+22% +$5.07M
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$28.9M 0.95%
255,719
– –
FPRX
23
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$26.3M 0.86%
+727,500
New +$32.1M
AVXS
24
DELISTED
AveXis, Inc. Common Stock
AVXS
$25.3M 0.83%
332,800
-20,000
-6% -$1.24M
PRTA icon
25
Prothena Corp
PRTA
$450M
$19.5M 0.64%
350,000
– –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2017 Portfolio in Review

As of Q1 2017, BB Biotech held 30 positions worth $3.06B, up 13% from $2.7B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Trading was light in Q1 2017: portfolio turnover was 3.3%. BB Biotech opened 1 new position and made no exits, leaving the 30-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier.

  • BB Biotech's largest Q1 2017 buy was Five Prime Therapeutics, Inc.: 727,500 shares worth $26.3M.
  • BB Biotech added most to Ionis Pharmaceuticals in Q1 2017, an estimated $24.6M increase.
  • BB Biotech's biggest Q1 2017 reduction was Incyte, cutting an estimated $49.7M.
  • BB Biotech's ten largest holdings make up 75% of its $3.06B portfolio in Q1 2017.
  • BB Biotech opened 1 new position and closed 0 in Q1 2017.
  • BB Biotech's portfolio value rose 13% quarter-over-quarter to $3.06B.

Based on BB Biotech's 13F filing for Q1 2017, filed 10 May 2017.